There is a certain kind of silence that surrounds rare diseases in India. Not because they are insignificant, but because they do not fit easily into the system that exists.
Most healthcare systems, including India's, are designed around volume. High patient load. Predictable disease patterns. Established treatment lines. Rare diseases disrupt that structure entirely. They appear infrequently, behave unpredictably, and often require therapies that sit outside the country's approved drug ecosystem.
So the problem is not always medical. Quite often, it is logistical, and legal.
A physician may know exactly what needs to be done. The protocol may be well documented internationally. But when the required drug is not approved or not marketed in India, the question shifts from what to treat with to how to access it at all.
This is where the idea of a Rare Disease Medicine Access Program becomes relevant. Not as a workaround, and certainly not as an informal arrangement, but as a deliberately constructed bridge between clinical necessity and regulatory control.
It is easy to assume that if a drug exists globally, it should eventually find its way into every major healthcare market. That assumption does not hold true for rare diseases.
Pharmaceutical companies make decisions based on a combination of regulatory effort and market viability. For drugs that serve a very small patient pool, the cost of entering a new market—filing, approvals, distribution setup—often outweighs the expected return.
India, despite its size, does not change that equation significantly for rare disease therapies. The patient base is fragmented, diagnosis rates are inconsistent, and pricing pressures are real. As a result, many drugs that are standard of care in other countries simply never get formally introduced here.
This creates a peculiar situation. The treatment exists. The evidence exists. Even the clinical consensus exists. But access remains out of reach.
The Named Patient Program in India is often explained in regulatory language. But if you look at how it actually functions on the ground, it is far more practical than theoretical. It begins with a doctor who has reached a point where available options are no longer sufficient. Not hypothetically insufficient, but in a very real, patient-specific sense.
Who is not responding to available treatments.
Whose condition is not stabilizing on standard therapy.
Where progression is outpacing available interventions.
At that stage, the doctor is not exploring alternatives casually. They are looking at treatments that are already in use elsewhere—sometimes for years—and asking a very direct question: Can this be brought in, legally, for this patient?
That is the entry point into a Named Patient pathway. What follows is not a quick process. It is documentation-heavy, deliberate, and in many cases, iterative. But it is also one of the few structured ways to convert global medical knowledge into actual treatment within India.
There is a tendency to assume that regulations slow things down unnecessarily. In this case, the opposite is true. Without a legal framework, there would be no legitimate way to import unapproved drugs at all.
The Drugs and Cosmetics Rules, 1945—particularly provisions like Rule 36 and Rule 37—do not exist to restrict access. They exist to define the conditions under which access can happen safely.
What they effectively say is this: If a drug is required for personal treatment, and if a qualified doctor is willing to take responsibility for prescribing it, then it may be imported in limited quantities, subject to approval.
That "subject to approval" is where the entire system rests. Because what is being evaluated is not just the drug, but the context:
The application—often routed through Form 12B—is not a formality. It is a justification document.
And the quality of that justification often determines how smoothly the process moves.
In standard practice, prescribing a drug is a routine act. In a Named Patient scenario, it becomes something else entirely.
The doctor is effectively stepping into a space where:
This is why such decisions are rarely made in isolation. In large hospitals, especially those dealing with rare diseases, these cases are often discussed internally. There is a degree of collective validation before moving forward—not as a formal requirement, but as a matter of professional responsibility.
Most patients respond to first-line chelating agents. But not all. Some develop intolerance. Others show inadequate response over time. When that happens, alternative therapies like Trientine hydrochloride become relevant.
Globally, this is not an unusual step. It is documented, studied, and accepted. But in India, if that drug is not readily available, the doctor has to bridge that gap manually—through an access request that aligns clinical reasoning with regulatory permission.
This is not just prescribing. It is advocacy, documentation, and accountability combined.
From the outside, it may seem like the difficult part is getting approval. In reality, that is only one part of the process.
Once approval is in place, the question becomes: how do you actually get the drug into the patient's hands without compromising quality?
Rare disease drugs are not like standard pharmaceuticals that can be shipped with minimal concern. Many of them:
Sourcing itself becomes a task. Not every supplier is reliable. Not every distributor is authorized.
This is where experienced intermediaries—often referred to as specialty access providers—become essential. They do not just "arrange" the drug. They manage risk. Because if something goes wrong at this stage, the consequence is not just delay. It can mean restarting the entire process.
One of the less discussed aspects of rare disease drug access is continuity. For many conditions, treatment is not a one-time intervention. It is ongoing—sometimes lifelong.
Which means the process does not end with one successful import. It repeats.
Every cycle involves:
For families and patients, this becomes part of life. Not just managing the disease, but managing access to treatment. And this is where the system is still evolving.
What most people don't see is that approval, even when it comes through, does not guarantee immediacy. There is still a physical journey the drug has to make—and that journey is where unpredictability enters.
India allows the import of unapproved drugs under defined conditions, but the drug itself originates from a different regulatory environment. That means two systems have to align:
Neither side is designed specifically for urgency. They are designed for control.
In practical terms, this means even after approval, delays can happen—batch release issues, documentation mismatches, customs queries. This is why experienced access providers don't just "process orders." They anticipate friction.
Rare disease drug access in India is not just a medical or regulatory challenge. It is, very often, a financial one.
| Cost Component | Details |
|---|---|
| Manufacturer pricing | Often already high for orphan drugs |
| International logistics | Cold-chain handling and shipping |
| Import duties & taxes | Applicable government levies |
| Service coordination costs | Access provider fees |
Unlike drugs available in the domestic market, there is no standardized pricing control mechanism here. Each case can look slightly different.
For therapies like enzyme replacements or advanced metabolic treatments, the cost can extend into lakhs per month. Even for oral therapies such as Trientine hydrochloride, long-term affordability becomes a consideration, especially when treatment spans years.
What makes this more complex is the lack of structured insurance support. Most patients still rely on:
There is a difference between inconvenience and clinical impact. In rare diseases, that line is often thin.
For progressive conditions, treatment gaps can lead to:
This is particularly relevant in disorders like:
While Wilson's disease provides a clear, relatable example, the dependence on structured drug access extends across a much broader spectrum.
Disease-modifying therapies have altered prognosis globally, but access in India has had to evolve gradually.
Enzyme replacement therapy is well established globally; India has made progress through government-supported programs.
Treatment access has historically depended on a mix of institutional support and individual import pathways.
Then there are conditions that do not yet have widespread recognition but are increasingly diagnosed due to advances in genetic testing:
There is an entire layer of the ecosystem that operates without much visibility—specialty pharmacies and rare disease access networks.
These are not retail pharmacies in the conventional sense. Their work sits somewhere between regulatory coordination and pharmaceutical logistics.
Organizations operating in this space typically handle:
What distinguishes experienced providers is not just their ability to source a drug, but their understanding of process continuity.
On paper, access pathways are described separately. In practice, they often overlap.
A patient might begin treatment under a compassionate use program, where a pharmaceutical company provides access during the pre-approval phase. Once that program ends, the same patient may transition into a Named Patient Program to continue therapy.
So when we talk about a Rare Disease Medicine Access Program, we are not referring to a single channel. We are referring to an ecosystem of interlinked pathways, each stepping in where another leaves off.
If there is one element that remains consistent across all these layers, it is compliance. Not as a bureaucratic requirement, but as a stabilizing force.
Because the moment drugs that are not approved in a country begin entering without control, the system loses credibility—and eventually, access itself becomes restricted.
This is why: every prescription is scrutinized, every import is documented, every batch is traceable. For patients, it can feel excessive. For regulators, it is necessary. And for the system as a whole, it is what allows these pathways to exist at all.
There is gradual movement in the right direction. India's approach to rare diseases is evolving:
At the same time, global pharmaceutical companies are becoming more aware of the need to expand access beyond primary markets. But these changes take time. And until the gap between global approval and local availability narrows significantly, Named Patient Programs and similar access pathways will continue to play a central role.
At its simplest level, a Rare Disease Medicine Access Program is about ensuring that geography does not become a barrier to treatment.
But in practice, it is far more layered than that.
It is:
It does not eliminate difficulty. It organizes it.
And for patients navigating rare diseases in India, that organization often makes the difference between knowing that a treatment exists and actually receiving it.